JAZZ Q2 2025 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.0B+2.1% YoY

Gross Profit

$929M88.9% margin

Operating Income

-$686M-65.6% margin

Net Income

-$718M-68.7% margin

EPS (Diluted)

$-11.74

QoQ Revenue Growth

+16.5%

Cash Flow

Operating Cash Flow

$89M

Free Cash Flow

$101M

Stock-Based Comp.

$65M

Balance Sheet

Total Assets

$10.9B

Total Liabilities

$7.2B

Stockholders' Equity

$3.7B

Cash & Equivalents

$1.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.0B	$1.0B	+2.1%
Gross Profit	$929M	$914M	+1.7%
Operating Income	-$686M	$199M	-444.2%
Net Income	-$718M	$169M	-526.2%

Revenue Segments

Xywav

$415M40%

Epidiolex/Epidyolex

$252M24%

Rylaze/Enrylaze

$101M10%

Zepzelca

$75M7%

High Sodium AG Oxybate Product Royalty Revenue

$54M5%

Defitelio/Defibrotide

$48M5%

Vyxeos

$45M4%

Xyrem

$35M3%

Other Royalty And Contract Revenues

$6M1%

Ziihera

$6M1%

Sativex

$5M0%

Other Products

$4M0%

Geographic Segments

UNITED STATES

$936M90%

Europe

$83M8%

Other Countries

$27M3%